China will become the third largest pharmaceutical market in the world in 2011

On March 16, 2010, IMS Health of the United States announced that the number of high-growth “emerging pharmaceutical markets” worldwide has increased from seven countries to seventeen, reflecting the development of the global pharmaceutical industry and the development of emerging countries and regions in the world. The trend of change. In the research report of IMS's “The New Wave of Emerging Pharmaceutical Markets: New Pattern of the New World”, from 2009 to 2013, the total pharmaceutical sales of these 17 countries are expected to increase by US$90 billion, which will account for 2013. The total growth of the pharmaceutical market is 48%, compared to 37% in 2009. The dramatic changes in the global economy, the development of the health care industry (such as the increase in the level of medical insurance and the increase in investment), and the change in the proportion of generic drugs and innovative drugs are all triggering market adjustments.

Mr. Murray Aitken, senior vice president of market analysis at IMS, said: “With the rapid increase in the share of the pharmaceutical market in emerging countries, the global pharmaceutical industry is forming a new pattern. In these changes, the Chinese market will become an independent In the meantime, there will be some growing “fast followers” ​​that will provide more opportunities for growth. These diversified markets have the characteristics of funding, provision, and distribution in healthcare. Not all the same, but overall, they all have the same strong growth factors, such as GDP growth, the establishment of a health and wellness system, and the improvement of the industry's regulatory environment."

IMS's research report also listed key factors in the continued slowdown in sales growth in mature markets, including: a large number of patents expired, high-speed market penetration of generic drugs, lack of funds for biopharmaceutical development, changes in Medicare reimbursement, and government’s product safety and The strict control of medical expenses and the macroeconomic situation.

In the review of global emerging economies, IMS applied its unique market assessment methods and forecasting capabilities to divide the emerging pharmaceutical market into three segments. The countries defined as emerging pharmaceutical markets have increased from seven in 2006 - China, Brazil, Mexico, India, Russia, South Korea and Turkey to the current 17. The report is based on the current GDP level of South Korea and reclassifies it to the "developed" pharmaceutical market.

The first plate: China. With China's GDP exceeding US$8 trillion, it is expected that China's pharmaceutical market will leap from the eighth place in 2006 to become the third place in the world. By 2013, China's annual pharmaceutical sales revenue will increase by more than US$40 billion, which is equivalent to the predicted growth of US pharmaceutical market sales during the same period. The growth of the Chinese pharmaceutical market still stems from the branded generic drugs that are produced and sold by existing local companies, although the demand for innovative products of multinational companies in China’s major central cities continues to grow.

The second plate: Brazil, Russia and India. These countries expect that the annual sales revenue of pharmaceuticals in 2013 will increase by 5 to 15 billion U.S. dollars. In recent years, both Brazil and Russia have achieved double-digit growth in drug sales, and India has benefited from an increase in the number of middle-class people, improvements in the health care system and the establishment of intellectual property laws and regulations.

The third section: "Fast followers." It is estimated that there are 13 other countries whose annual drug sales revenue in 2013 will increase by 1 to 5 billion U.S. dollars. They are: Venezuela, Poland, Argentina, Turkey, Mexico, Vietnam, South Africa, Thailand, Indonesia, Romania, Egypt, Pakistan and Ukraine. Although each market has its own characteristics, they all have common features such as complex, active and rapid changes.

David Campbell, Senior Principal of IMS's Emerging Pharmaceutical Marketing Department, said, “Different sectors in the emerging markets have new opportunities for the pharmaceutical industry. We believe that the pioneers will have a clear advantage. Those pharmaceutical companies that entered the market first, If we can build our organizational capabilities based on the characteristics of these emerging pharmaceutical markets and optimize our product mix and business model, we will benefit from differentiation and market share.”

Cotton Yarn Series

Organic Cotton Yarn,Organic Hemp Yarn,Pure Cotton Yarn,Cotton Modal Yarn

Henan Xianghe Medical Materials Co., Ltd. , https://www.xiangheweicai.com